Fosun Pharma and Amgen have jointly announced a collaboration and license agreement for Fosun Pharma for the commercialization of Amgen’s Otezla and Parsabiv in the Chinese Mainland.

The collaboration will enable Amgen to bring the two innovative medicines to Chinese patients with psoriasis and chronic kidney disease more quickly by leveraging Fosun Pharma’s commercial capabilities within China.

Wu Yifang, Chairman of Fosun Pharma said: “We are very pleased to enter into this partnership with Amgen to bring two innovative medicines, Otezla and Parsabiv, to Chinese patients."

Otezla (apremilast tablets) was approved by the National Medical Products Administration of China (NMPA) in August 2021 for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. This approval makes Otezla the first and currently the only oral phosphodiesterase 4 (PDE4) inhibitor for the treatment of plaque psoriasis in China.

Parsabiv has been approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) in November 2016 and February 2017 respectively for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Currently Parsabiv is in the process of market authorization approval (MAA) in China. SHPT is one of the common complications of CKD patients on hemodialysis.